Read by QxMD icon Read

Current Radiopharmaceuticals

M Picchio, F De Cobelli, P Mapelli
No abstract text is available yet for this article.
April 4, 2019: Current Radiopharmaceuticals
Efrain Araujo Perini, Mikhail Skopchenko, Tran Thu Hong, Rahmat Harianto, Alexis Maître, Maidelys Rosa Rodríguez Rodríguez, Nathalia de Oliveira Santos, Yinglei Guo, Xiangyu Qin, Carlos A Zeituni, Valeriia N Starovoitova
BACKGROUND: A significant number of developing countries have no facilities producing medical radioisotopes. OBJECTIVE: In this paper we show that access to life-saving radioisotopes and radiopharmaceuticals and the geographical distribution of corresponding infrastructure is highly unbalanced worldwide. METHODS: We discuss the main issues which need to be addressed in order to establish the production of radioisotopes and radiopharmaceuticals, which are especially important for developing countries as newcomers in the field...
March 28, 2019: Current Radiopharmaceuticals
Angela Carollo, Stefano Papi, Chiara M Grana, Luigi Mansi, Marco Chinol
BACKGROUND: Neuroendocrine tumors (NETs) are relatively rare tumors, mainly originating from the digestive system, that tend to be slow growing and are often diagnosed when metastatized. Surgery is the sole curative option but is feasible only in a minority of patients. Among them, pancreatic neuroendocrine tumors (pancreatic NETs or pNETs) account for less than 5% of all pancreatic tumors. Viable therapeutic options include medical treatments such as biotherapies and more recently peptide receptor radionuclide therapies (PRRT) with radiolabeled somatostatin analogues...
March 5, 2019: Current Radiopharmaceuticals
Vittorio Briganti, Vincenzo Cuccurullo, Giuseppe Danilo Di Stasio, Luigi Mansi
BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) are rare neoplasms, sporadic or familial, even being part of a syndrome. Their diagnosis is based on symptoms, hormonal disorders or may be fortuitous. The role of Nuclear Medicine is important, mainly because of the possibility of a theranostic strategy. This approach is allowed by the availability of biochemical agents, which may be labeled with radionuclides suitable for diagnostic or therapeutic purposes, showing almost identical pharmacokinetics...
March 1, 2019: Current Radiopharmaceuticals
Dheyauldeen Shabeeb, Mansoor Keshavarz, Alireza Shirazi, Gholamreza Hassanzadeh, Mohammed Reza Hadian, Azin Nowrouzi, Masoud Najafi, Ahmed Eleojo Musa
BACKGROUND: Radiotherapy (RT) is a treatment method for cancer using ionizing radiation (IR). The interaction between IR with tissues produces free radicals that cause biological damages.As the largest organ in the human body, the skeletal muscles may be affected by detrimental effects of ionizing radiation. To eliminatethese side effects, we used melatonin, a major product secreted by the pineal gland in mammals, as a radioprotective agent. MATERIALS AND METHODS: For this study, a total of sixty male Wistar rats were used...
February 19, 2019: Current Radiopharmaceuticals
Muhammad Affan Zamir, Wasim Hakim, Siraj Yusuf, Robert Thomas
INTRODUCTION: Pancreatic neuroendocrine tumours (p-NETs) are an important disease entity and comprise of peptide-secreting tumours often with a functional syndrome. Accounting for a small percentage of all pancreatic tumours, they have a good overall survival rate when diagnosed early, with surgery being curative. The role of nuclear medicine in the diagnosis and treatment of these tumours is evident. However, the vast majority of patients will require extensive imaging in the form of conventional radiological techniques...
February 14, 2019: Current Radiopharmaceuticals
Vincenzo Cuccurullo, Giuseppe Danilo Di Stasio, Luigi Mansi
BACKGROUND: Pancreatic neuroendocrine tumors (P-NETs) are a challenge in terms of both diagnosis and therapy; morphological studies need to be frequently implemented with non standard techniques such as Endoscopic Ultrasounds , Dynamic CT, functional Magnetic Resonance. DISCUSSION: The role of nuclear medicine's, being scarcely sensitive F-18 Fluorodeoxyglucose, is mainly based on the over-expression of somatostatin receptors (SSTR) on neuroendocrine tumor cells surface...
February 5, 2019: Current Radiopharmaceuticals
Wei Fang, Shuang Liu
OBJECTIVE: Myocardial perfusion imaging (MPI) with radiotracers is an integral component in evaluation of the patients with known or suspected coronary artery diseases (CAD). 99mTc-Sestamibi and 99mTc-Tetrofosmin are commercial radiopharmaceuticals for MPI by single photon-emission computed tomography (SPECT). Despite their widespread clinical applications, they do not meet the requirements of an ideal perfusion imaging agent due to their inability to linearly track the regional myocardial blood flow rate at >2...
February 5, 2019: Current Radiopharmaceuticals
Shahad Alsadik, Siraj Yusuf, Adil Al-Nahhas
BACKGROUND: The incidence of pancreatic neuroendocrine tumours (pNETs) has increased considerably in the last few decades. The characteristic features of this tumour and the development of new investigative and therapeutic methods had a great impact on its management. OBJECTIVE: The aim of this review is to investigate the outcome of Peptide Receptor Radionuclide Therapy (PRRT) in treatment of pancreatic neuroendocrine tumours. METHODS: A comprehensive literature search strategy was used based on two databases (SCOPUS, and PubMed)...
February 1, 2019: Current Radiopharmaceuticals
Laura Evangelista, Cuppari Lea, Bellu Luisa, Bertin Daniele, Caccese Mario, Reccia Pasquale, Zagonel Vittorina, Lombardi Giuseppe
PURPOSES: The aims of the present study were to: 1- critical assess the utility of L-3,4-dihydroxy-6-18Ffluoro-phenyl-alanine (18F-DOPA) and O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) positron emission tomography (PET)/computed tomography (CT) in patients with high grade glioma (HGG) and 2- describe the results of 18F-DOPA and 18F-FET PET/CT in a case series of patients with recurrent HGG. MATERIALS AND METHODS: We searched for studies using the following databases: PubMed, Web of Science and Scopus...
January 15, 2019: Current Radiopharmaceuticals
Carina Stegmayr, Antje Willuweit, Philipp Lohmann, Karl-Josef Langen
OBJECTIVES: In recent years, PET using radiolabelled amino acids has gained considerable interest as an additional tool besides MRI to improve the diagnosis of cerebral gliomas and brain metastases. A very successful tracer in this field is O-(2-[18F]fluoroethyl)-L-tyrosine (FET) which in recent years has replaced short lived tracers such as [11C]-methyl-L-methionine in many neuro-oncological centers in Western Europe. FET can be produced with high efficiency and distributed in a satellite concept like 2-[18F]fluoro-2-deoxy-D-glucose...
January 10, 2019: Current Radiopharmaceuticals
Alban Revy, François Hallouard, Sandrine Joyeux-Klamber, Andrea Skanjeti, Catherine Rioufol, Marc Fraysse
OBJECTIVE: Recent gallium-68 labeled peptides are of increasing interest for PET imaging in nuclear medicine. Somakit TOC® is a radiopharmaceutical kit registered in the European Union for the preparation of [68Ga]Ga-DOTA-TOC used for the diagnosis of neuroendocrine tumors. Development of a labeling process using a synthesizer is particularly interesting for quality and reproducibility of the final product although only manual processes are described in the Summary of Product (SmPC) of the registered product...
January 10, 2019: Current Radiopharmaceuticals
Suchitil Rivera-Marrero, Laura Fernández-Maza, Samila León-Chaviano, Marquiza Sablón-Carrazana, Alberto Bencomo-Martónez, Alejandro Perera-Pintado, Anais Prats-Capote, Florencia Zoppolo, Ingrid Kreimerman, Tania Pardo, Laura Reyes, Marcin Balcerzyk, Geyla Dubed-Bandomo, Daymara Mercerón-Martónez, Luis A Espinosa-Rodróguez, Henry Engler, Eduardo Savio, Chryslaine Rodróguez-Tanty
BACKGROUND: Alzheimer's disease (AD) is the most common form of dementia. Neuroimaging methods have widened the horizons for AD diagnosis and therapy. The goals of this work are the following: i) the synthesis of 2-(3-fluoropropyl)-6-methoxynaphthalene (5) and its [18F]-radiolabeled counterpart ([18F]Amylovis), ii) the in silico and in vitro comparative evaluations of [18F]Amylovis and [11C]Pittsburg compound B (PIB) and iii) the in vivo preclinical evaluation of [18F]Amylovis in transgenic and wild mice...
January 2, 2019: Current Radiopharmaceuticals
Ratna Sekhar Bolla, Narasimha Murthy Gandikota, Ivaturi Venkata Kasi Viswanath
OBJECTIVE: Stable and non-radioactive isotope labeled compounds gained significance in recent drug discovery and other various applications such as bio-analytical studies. The modern bioanalytical techniques can study the adverse therapeutic effects of drugs by comparing isotopically labeled internal standards. A well-designed labeled compound can provide high-quality information about the identity and quantification of drug-related compounds in biological samples. This information can be very useful at key decision points in drug development...
2019: Current Radiopharmaceuticals
Luigi Mansi, Sean L Kitson
No abstract text is available yet for this article.
2019: Current Radiopharmaceuticals
Elisabetta Giovannini, Giampiero Giovacchini, Elisa Borsò, Patrizia Lazzeri, Mattia Riondato, Rossella Leoncini, Valerio Duce, Andrea Ciarmiello
OBJECTIVE: Neuroendocrine neoplasms (NENs) are generally defined as rare and heterogeneous tumors. The gastrointestinal system is the most frequent site of NENs localization, however they can be found in other anatomical regions, such as pancreas, lungs, ovaries, thyroid, pituitary, and adrenal glands. Neuroendocrine neoplasms have significant clinical manifestations depending on the production of active peptide. METHODS: Imaging modalities play a fundamental role in initial diagnosis as well as in staging and treatment monitoring of NENs, in particular they vastly enhanced the understanding of the physiopathology and diagnosis of NENs through the use of somatostatin analogue tracers labeled with appropriate radioisotopes...
December 11, 2018: Current Radiopharmaceuticals
Omer Sager, Ferrat Dincoglan, Selcuk Demiral, Bora Uysal, Hakan Gamsiz, Yelda Elcim, Esin Gundem, Bahar Dirican, Murat Beyzadeoglu
BACKGROUND AND OBJECTIVE: Although accounting for a relatively small proportion of all lung cancers, small cell lung cancer (SCLC) remains to be a global health concern with grim prognosis. Radiotherapy (RT) plays a central role in SCLC management either as a curative or palliative therapeutic strategy. There has been considerable progress in RT of SCLC thanks to improved imaging techniques leading to accurate target localization for precise delivery of RT. Positron emission tomography (PET) is increasingly used in oncology practice as a non-invasive molecular imaging modality...
November 20, 2018: Current Radiopharmaceuticals
Dheyauldeen Shabeeb, Masoud Najafi, Ahmed Eleojo Musa, Mansoor Keshavarz, Alireza Shirazi, Gholamreza Hassanzadeh, Mohammed Reza Hadian, Hedayat Samandari
BACKGROUND: Radiotherapy is one of the treatment methods for cancers using ionizing radiations. About 70% of cancer patients undergo radiotherapy. Radiation effect on the skin is one of the main complications of radiotherapy and dose limiting factor. To ameliorate this complication, we used melatonin as a radioprotective agent due to its antioxidant and anti-inflammatory effects, free radical scavenging, improving overall survival after irradiation as well as minimizing the degree of DNA damage and frequency of chromosomal abrasions...
November 20, 2018: Current Radiopharmaceuticals
William Sun, Cheryl Falzon, Ebrahim Naimi, Ali Akbari, Leonard I Wiebe, Manju Tandon, Piyush Kumar
BACKGROUND: 1-α-D-(5-Deoxy-5-[18F]fluoroarabinofuranosyl)-2-nitroimidazole ([18F]FAZA) is manufactured by nucleophilic radiofluorination of 1-&alpha;-D-(2',3'-di-O-acetyl-5'-O-toluenesulfonylarabinofuranosyl)-2-nitroimidazole (DiAcTosAZA) and alkaline deprotection to afford [18F]FAZA. High yields (>60%) under optimized conditions frequently revert to low yields (<20%) in large scale, automated syntheses. Competing side reactions and concomitant complex reaction mixtures contribute to substantial loss of product during HPLC clean-up...
October 18, 2018: Current Radiopharmaceuticals
Afrouz Asgari, Mansour Ashoor, Leila Sarkhosh, Abdollah Khorshidi, Parvaneh Shokrani
OBJECTIVE: The characterization of cancerous tissue and bone metastasis can be distinguished by the accurate assessment of accumulated uptake and activity from different radioisotopes. The various parameters and phenomena such as calibration factor, Compton scattering, attenuation and penetration are influenced intrinsic this quantity, and the qualification of images as well. METHODS: The camera calibration factor (CF) translates reconstructed count map into absolute activity map, is determined by both planar and tomographic scans using different phantom geometries...
September 13, 2018: Current Radiopharmaceuticals
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"